IntelGenx Announces First Parkinson's Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 'MONTPARK' Clinical Trial -April 08, 2024 at 07:45 am EDT

SAINT LAURENT, Quebec, April 08, 2024 -- IntelGenx Corp.  today announced that Montelukast VersaFilm® has been administered to the first Parkinson’s Disease patients in the Phase 2 clinical...

Related Keywords

Sweden ,Quebec ,Canada ,United States ,Saint Laurent ,Canadian ,Swedish ,Dwight Gorham ,Stephen Kilmer ,Andre Godin ,Montelukast Versafilm ,Exchange Commission ,Intelgenx Corp ,Drug Administration ,Swedish University ,Intelgenx Technologies Corp ,World Health Organization ,Parkinson Foundation ,Securities Exchange ,Karolinska University Hospital ,Company Or Intelgenx ,Per Svenningsson ,Lead Principal ,Health Organization ,Leukotriene Receptor Antagonist Montelukast ,Looking Information ,Securities Exchange Act ,Securities Act ,United States Securities ,Intelgenx Technologies ,Markets ,